Welcome to our dedicated page for Cardio Diagnostics Holdings news (Ticker: CDIO), a resource for investors and traders seeking the latest updates and insights on Cardio Diagnostics Holdings stock.
Cardio Diagnostics Holdings, Inc. reports developments in precision cardiovascular medicine, including AI-driven genetic and epigenetic blood tests for coronary heart disease. The company’s commercial products include Epi+Gen CHD, which assesses three-year risk for a coronary heart disease event, and PrecisionCHD, which aids in CHD diagnosis and management.
Recurring updates include clinical data for cardiovascular disease detection, CMS reimbursement and MolDX payment-rate activity, provider-network expansion, community health partnerships, and commercialization efforts for physician-ordered testing. Company communications also describe its Integrated Genetic-Epigenetic Engine and broader cardiovascular disease prevention, detection, and management strategy.
Cardio Diagnostics (Nasdaq: CDIO) has begun in-house processing at its new high-complexity, CLIA-certified laboratory in Iowa City, Iowa, gaining end-to-end control over its multi-omics cardiovascular tests, Epi+Gen CHD™ and PrecisionCHD™. The lab was staffed, equipped, and licensed within a year, receiving its federal CLIA license with no deficiencies and securing additional state licenses in California, Maryland, Rhode Island, and Pennsylvania, while pursuing New York certification. In-house operations replace prior third-party processing, aiming to improve cost control, unit economics, and test margins, with the company expecting approximately 40% gross margins at scale. The facility currently offers a 7–10 business day turnaround from sample receipt and includes a research lab focused on precision epigenetic monitoring to support more targeted cardiovascular care.
Cardio Diagnostics (Nasdaq: CDIO) will host an investor conference call on Thursday, August 20, 2026, at 3 p.m. Central Time. The call will cover its precision molecular approach to cardiovascular disease, updates on Epi+Gen CHD and PrecisionCHD tests, ongoing and planned studies, reimbursement progress, and strategic growth initiatives. Investors can join via webcast or telephone, with a replay available after the event.
Cardio Diagnostics (Nasdaq: CDIO) announced that Atlas Healthcare Physicians (AHP), a Southern California independent physician association, will cover its Epi+Gen CHD and PrecisionCHD blood tests with prior authorization starting May 2026.
The tests assess three-year coronary heart disease risk and aid CHD diagnosis without radiation, fasting, or special infrastructure, supporting earlier detection and personalized cardiovascular care across AHP’s Los Angeles and Orange County network.
Cardio Diagnostics (Nasdaq: CDIO) will showcase its precision cardiovascular solutions at four national benefits conferences in June 2026. The company will engage employers, brokers, unions, and plan administrators on using its blood tests and analytics platform to address cardiovascular disease, a major benefits cost driver.
Offerings include clinically validated tests Epi+Gen CHD, PrecisionCHD, and the HeartRisk population insights platform, aimed at identifying at-risk individuals earlier, supporting preventive care, and helping reduce direct and indirect cardiovascular-related costs for health plans and workforces.
Cardio Diagnostics (Nasdaq: CDIO) will host an investor conference call on Wednesday, February 18, 2026 at 3:00 p.m. Central Time to review its precision molecular approach to cardiovascular disease prevention and early detection.
The call will cover commercial tests Epi+Gen CHD and PrecisionCHD, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. A live webcast and dial-in access are provided; a replay will be available after the call.
Cardio Diagnostics (Nasdaq: CDIO) will host an investor conference call on Thursday, February 19, 2026 at 3:00 p.m. Central Time.
The call will review the company’s precision molecular approach, updates on commercially available tests Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. A webcast and replay are available.
Cardio Diagnostics (NASDAQ: CDIO) announced a strategic agreement with Aimil and Dr. Lal PathLabs to launch the PrecisionCHD™ blood test in India. This marks Cardio Diagnostics’ first expansion outside the United States and targets earlier detection and personalized management of coronary heart disease (CHD).
PrecisionCHD combines epigenetics, genetics and AI to detect obstructive and non‑obstructive CHD, including INOCA and MINOCA; supporting data were presented at the American Heart Association Scientific Sessions. Initial integration into Dr. Lal PathLabs’ network (290+ labs, 300+ MD pathologists) has begun, with commercial rollout expected in 2026.
Cardio Diagnostics (Nasdaq: CDIO) announced a community partnership with the Southdale YMCA in Edina, Minnesota to expand heart health education and AI‑powered cardiovascular testing.
Key details: the Southdale YMCA serves ~14,000 members (about 80% adults). Cardio Diagnostics will host an in‑person education session on January 26, 2026 at 11:30 AM CT and participate in the Southdale YMCA Heart Health Fair on February 25, 2026, 8 AM–4 PM CT. Discounted clinician‑ordered tests Epi+Gen CHD (three‑year CHD risk) and PrecisionCHD will be available via telemedicine, at‑home kits, or onsite blood collection.
Cardio Diagnostics (Nasdaq: CDIO) announced that the Centers for Medicare and Medicaid Services (CMS) finalized a $854 gapfill payment rate for both Epi+Gen CHD™ and PrecisionCHD™ tests, effective for dates of service on or after January 1, 2026. The final rate increases from preliminary gapfill rates of $350 for Epi+Gen CHD and $684.76 for PrecisionCHD. Both tests have dedicated CPT PLA codes, 0439U (Epi+Gen CHD) and 0440U (PrecisionCHD), effective April 1, 2024. The company characterized the final rate as a step toward expanding Medicare access to its AI-driven cardiovascular tests.
Cardio Diagnostics (Nasdaq: CDIO) will present data at the American Heart Association Scientific Sessions (New Orleans, Nov 7–10, 2025) showing that its PrecisionCHD epigenetic-genetic blood test can detect INOCA and MINOCA presentations. In a University of Iowa collaboration of 267 hospitalized acute coronary syndrome patients, methylation indices from PrecisionCHD detected INOCA with an overall AUC of 0.90 and provided molecular phenotyping to inform personalized care.
The release notes prior validation in three independent cohorts published in the Journal of the American Heart Association and emphasizes potential use in women, rural patients, telemedicine, and settings lacking invasive provocative testing.